Centre for Heart Lung Innovation, Providence Health Care Research Institute
Dr. Singh received his Honours BSc in Biology and Mathematics from McMaster University (2010) and PhD in Experimental Medicine from the University of British Columbia under the supervision of Dr. Scott Tebbutt (2016). Dr. Singh then pursued a post-doctoral fellowship with the PROOF Centre of Excellence with Drs. Bruce McManus and Raymond Ng (2016-2020). Dr. Singh was a principal statistical analyst at Bayer Pharmaceuticals prior to starting his faculty appointment in 2022 in Heart and Lung Pharmacogenomics.
Dr. Singh laboratory is a computational biology lab focused on biomarker discovery and developing methods and tools for multiomics data integration and visualization. Dr. Singh’s research focuses on the identification of biomarkers for heart and lung disease such as asthma and heart failure using high throughput biological (“omics”) datasets. Dr. Singh developed DIABLO, an integrative multiomics classification method as part of the mixOmics data integration project (mixomics.org). Through active collaborations with clinicians and wet-bench scientists, Dr. Singh’s research incorporates patient cohorts with model systems with single cell and spatial technologies dissecting molecular mechanisms of disease, for the eventual goal of drug repurposing.
General Research Interest(s)
Cardiopulmonary Sciences and anesthesiology
Multiomics data integration
Single cell omics
HLI Trainee Association (TAHLI), Respect, Equity, Diversity and Inclusion (REDI) committee, Precision Health Initiative (PHI)